Quick Answer
GRI Bio, Inc. reported Diluted EPS of $121.80 per share (loss) for fiscal year 2025.
GRI Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$121.80 | +92.1% |
| 2024 | -$1545.55 | +69.2% |
| 2023 | -$5018.09 | -20012.6% |
| 2022 | -$24.95 | -1657.0% |
| 2021 | -$1.42 | -32.7% |
| 2020 | -$1.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.28 | +88.8% | +2.3% |
| June 30, 2025 | -$1.31 | +97.9% | +77.4% |
| March 31, 2025 | -$5.80 | +94.3% | +49.2% |
| September 30, 2024 | -$11.42 | +82.6% | +81.5% |
| June 30, 2024 | -$61.85 | +74.2% | +38.8% |
| March 31, 2024 | -$101.05 | -571.9% | -53.6% |
| September 30, 2023 | -$65.78 | -16766.7% | +72.5% |
| June 30, 2023 | -$239.37 | -68291.4% | -1491.6% |
- GRI Bio, Inc. showed an increase of +92.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, GRI Bio, Inc.’s diluted eps has declined by 11283.2% (from $1.07 per share (loss) to $121.80 per share (loss)).
- The most recent figure is from GRI Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: